Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 10Urinary Bladder Neoplasms 7Prostatic Neoplasms 6Breast Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Carcinoma, Transitional Cell 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Recurrence 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Hematologic Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urologic Neoplasms 1Thrombocytosis 1Stroke 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1

Interventions

rocakinogene sifuplasmid 1durvalumab 1VGX-3100 1MEDI0457 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anal Canal Carcinoma × Disulfides × Genitourinary × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡